MED16

Across TCGA pan-cancer cohorts, MED16 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED16 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MED16 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MED16 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where MED16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.885	1.000	.002	31	view →
LSCC	DFS	Median	II,III,IV	0.858	0.524	.005	17	view →
LUAD	DFS	Median	II,III,IV	0.956	0.750	.002	10	view →
HNSC	OS	Median	All	0.798	0.898	.029	4	view →
PDAC	DFS	Tertile	II,III,IV	0.645	0.843	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED16–CCRCC (OS)

Open the CCRCC breakdown →